Drug General Information |
Drug ID |
D0C1NP
|
Former ID |
DIB019520
|
Drug Name |
compound 4g
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
|
Formula |
C13H13NO5
|
InChI |
InChI=1S/C13H13NO5/c1-13(2)11(16)14(12(17)19-13)10(15)8-4-6-9(18-3)7-5-8/h4-7H,1-3H3
|
InChIKey |
ZYRNCIWULACSEK-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
|
Target and Pathway |
Target(s) |
Leukocyte proteinase-3 |
Target Info |
Inhibitor |
[1]
|
Cathepsin G |
Target Info |
Inhibitor |
[1]
|
Leukocyte elastase |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
Lysosome
|
Renin-angiotensin system
|
Amoebiasis
|
Systemic lupus erythematosushsa05202:Transcriptional misregulation in cancer
|
Systemic lupus erythematosus
|
Pathway Interaction Database
|
C-MYB transcription factor networkupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalingupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
C-MYB transcription factor network
|
Reactome
|
Common Pathway of Fibrin Clot FormationR-HSA-1474228:Degradation of the extracellular matrix
|
Activation of Matrix Metalloproteinases
|
Metabolism of Angiotensinogen to Angiotensins
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)R-HSA-1442490:Collagen degradation
|
Degradation of the extracellular matrix
|
WikiPathways
|
ACE Inhibitor Pathway
|
Regulation of Insulin-like Growth Factor (IGF) Transport and Uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)WP2840:Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
Human Complement System
|
Degradation of collagen
|
References |
REF 1 | N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3993-7. |